Ubs Asset Management Americas Inc Ngm Biopharmaceuticals Inc Transaction History

Ubs Asset Management Americas Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $2,264 - $8,585	664 Added 2.16%	31,431 $157,000
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $49,050 - $68,842	-3,896 Reduced 11.24%	30,767 $402,000
Q2 2022 Aug 12, 2022	BUY	$10.58 - $17.5 $169,639 - $280,595	16,034 Added 86.07%	34,663 $444,000
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $109,014 - $139,078	-6,316 Reduced 25.32%	18,629 $329,000
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $297,293 - $386,407	14,754 Added 144.77%	24,945 $524,000
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $153,476 - $306,035	10,191 New	10,191 $200,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.